Effective treatment by reprofiling an existing drug to save lives from COVID-19 lung damage


Vicente Salinas (See Profile)




Development, market readiness, clinical trial



It could prevent deaths by COVID and its mutations because it reduces the inflammation responsible for lung injury

Time to market of only 4 months worldwide because of the repositioning of an existing drug

Protected by industrial property rights by means of a worldwide patent application for its indication for COVID

Only winning pharmacological project of the pan-European hackathon #EUvsVirus organized by European Commission

A USA pharma listed on NASDAQ has just started in NY a Phase III clinical trial for COVID with a similar drug

This information is confidential, do not share or copy.

Under evaluation at least till: 7th June

If you want to have more information or you want to review the project, you have to login or register

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies

Log in with your credentials


Forgot your details?

Create Account

Skip to toolbar